0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Research Letters | ONLINE FIRST

Poor Benefit/Risk Balance of Intravenous Immunoglobulins in DRESS FREE

Pascal Joly, MD, PhD; Baptiste Janela, PhD; Florence Tetart, MD; Sylvie Rogez, MD, PhD; Damien Picard, MD; Michel D’Incan, MD, PhD; Vincent Descamps, MD, PhD; Evelyne Collet, MD; Jean Claude Roujeau, MD, PhD; Philippe Musette, MD, PhD
[+] Author Affiliations

Author Affiliations: INSERM U905 (Drs Joly, Janela, Picard, and Musette) and Department of Dermatology (Drs Joly, Tetart, Picard, and Musette), Rouen University Hospital, Rouen, France; Department of Virology, Limoges University Hospital, Limoges, France (Dr Rogez); and Departments of Dermatology at Clermont-Ferrand University Hospital, Clermont Ferrand (Dr D’Incan), Hôpital Bichat (AP-HP), Paris (Dr Descamps), Dijon University Hospital, Dijon (Dr Collet), and Groupe hospitalier Albert Chenevier–Henri Mondor (AP-HP), Créteil (Dr Roujeau), France.


Arch Dermatol. 2012;148(4):543-544. doi:10.1001/archderm.148.4.dlt120002-c.
Text Size: A A A
Published online

Drug reaction with eosinophilia and systemic symptoms (DRESS), sometimes called hypersensitivity syndrome, is a severe drug-induced reaction with visceral involvement and blood abnormalities associated with reactivations of viruses of the herpes family: human herpesvirus (HHV)-6 HHV-7, Epstein-Barr virus (EBV), and cytomegalovirus (CMV).1 Our research group2 recently reported that the immune response in DRESS, previously thought to be directed against drug components, is in fact mediated by tumor necrosis factor (TNF)–and interferon-γ (INF-γ)–secreting CD8+ T lymphocytes, which are directed against previously quiescent HHVs reactivated by the drug and home to the skin and visceral organs.2 Oral corticosteroid treatment is often proposed for severe DRESS, but oral corticosteroids might favor a relapsing course of the syndrome. Some researchers,3,4 based on the presence of antiviral IgGs in intravenous immunoglobulins (IVIGs) and their numerous immunologic effects, have suggested that IVIGs might be effective in a few patients with DRESS, although these patients were concomitantly treated with systemic corticosteroids. The aim of the present study was to evaluate the safety and efficacy of IVIGs in patients with DRESS and to assess the evolution of immunologic and virologic parameters after treatment.

Ten patients with severe DRESS2 were considered for enrollment in this multicenter prospective open study, which was approved by the Northwest France ethics committee and registered as NCT00505648. Six patients were ultimately enrolled. Study patients were treated with IV infusions of Tegeline (LFB Biomedicaments), 200 mg/kg/d for 5 consecutive days. The primary end point was the disappearance of fever and disease progression by day 7 after treatment and complete remission without corticosteroids by day 30. The study was prematurely stopped by the ethics committee for safety reasons. To assess the role of IVIGs on viral reactivations and immunologic parameters, blood samples were collected at baseline and at days 5 (end of IVIG treatment), 10, and 30. Viral DNA from EBV, HHV-6, HHV-7, and CMV was quantified by real-time polymerase chain reaction in patients' serum and peripheral blood mononuclear cells.2

Six patients with severe DRESS (2 men and 4 women), mean (SD) age 58 (15) years, were included in the study (Table). All patients had an extensive eruption and facial swelling. According to the RegiSCAR scale,5 the patients' median severity score was 7 (range, 6-7) on a scale ranging from 1 to 9, meaning that the diagnosis of DRESS was certain in all patients. Patients were treated after a median delay of 12.5 days (range, 7-24 days) after the onset of DRESS. Two patients experienced severe malaise during the infusion, one with hypertension and the other with hypotension, and so infusion was stopped by the investigators. One patient had a pulmonary embolism at day 9.

Table Graphic Jump LocationTable. Clinical, Biologic, and Virologic Parameters at Baseline and After Treatment in the 6 Patients With DRESS Treated With IVIGs

Four patients required rescue oral corticosteroid treatment, the 2 patients with initial malaise and 2 others owing to the occurrence of hemophagocytic syndrome during the follow-up period. These 4 patients dropped out of the study, according to the study protocol (ie, rescue corticosteroid treatment). Only 1 of 6 patients achieved the primary end point. This patient was in partial remission at day 30 and achieved complete remission by day 120.

Viral reactivations were observed at baseline in all 6 cases and were still observed after treatment in 3 of the 3 cases tested (Table). Immunologic analyses showed a slight decrease in TNF and INF-γ serum levels from baseline to day 30 in the 2 patients who achieved partial or complete remission with IVIG treatment alone, whereas the number of TNF- and INF-γ–producing CD8+ T lymphocytes paradoxically increased despite the regression of DRESS symptoms in these patients.

This study does not support a beneficial effect of IVIG treatment in patients with DRESS, since 5 of 6 patients experienced severe adverse events, and 4 patients had to be treated with oral corticosteroids because of IVIG adverse effects (n = 2) or uncontrolled DRESS (n = 2). This absence of beneficial effect of IVIGs is in accordance with the persistence of multiple viral reactivations after treatment, which was previously reported in a patient with DRESS treated with IVIGs,4 and with the absence of significant modification of immunologic parameters in patients who did not receive oral corticosteroids. Our observations suggest that IVIGs must not be used as a single treatment in DRESS.

Correspondence: Dr Joly, Clinique Dermatologique, Hôpital Charles Nicolle, 1 rue de Germont, 76031 Rouen CEDEX, France (Pascal.Joly@chu-rouen.fr).

Published Online: December 19, 2011. doi:10.1001/archdermatol.2011.1937

Author Contributions: All authors had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Joly, Collet, and Musette. Acquisition of data: Joly, Janela, Tetart, Rogez, Picard, D’Incan, Descamps, Collet, Roujeau, and Musette. Analysis and interpretation of data: Joly, Janela, Rogez, Picard, Collet, and Musette. Drafting of the manuscript: Joly, Janela, Collet, and Musette. Critical revision of the manuscript for important intellectual content: Joly, Janela, Tetart, Rogez, Picard, D’Incan, Descamps, Collet, Roujeau, and Musette. Statistical analysis: Joly, Janela, and Collet. Obtained funding: Joly, Janela, Collet, and Musette. Administrative, technical, and material support: Joly, Janela, Rogez, Picard, Descamps, Collet, and Musette. Study supervision: Joly, Collet, and Musette.

Financial Disclosure: Dr Roujeau has served as expert consultant to LFB Biomedicaments on topics of dermatomyositis and autoimmune blistering diseases.

Funding/Support: This study was supported by the French Society of Dermatology, a national program of clinical research (Programme Hospitalier de Recherche Clinique). The IVIGs were provided by LFB Biomedicaments, Les Ulis, France.

Role of the Sponsors: The sponsors had no role in the design and conduct of the study; in the collection, analysis, and interpretation of data; or in the preparation, review, or approval of the manuscript.

Additional Contributions: Richard Medeiros edited the manuscript.

Tohyama M, Hashimoto K, Yasukawa M,  et al.  Association of human herpesvirus 6 reactivation with the flaring and severity of drug-induced hypersensitivity syndrome.  Br J Dermatol. 2007;157(5):934-940
PubMed   |  Link to Article
Picard D, Janela B, Descamps V,  et al.  Drug reaction with eosinophilia and systemic symptoms (DRESS): a multiorgan antiviral T cell response.  Sci Transl Med. 2010;2(46):46ra62
PubMed   |  Link to Article
Fields KS, Petersen MJ, Chiao E, Tristani-Firouzi P. Case reports: treatment of nevirapine-associated dress syndrome with intravenous immune globulin (IVIG).  J Drugs Dermatol. 2005;4(4):510-513
PubMed
Kano Y, Inaoka M, Sakuma K, Shiohara T. Virus reactivation and intravenous immunoglobulin (IVIG) therapy of drug-induced hypersensitivity syndrome.  Toxicology. 2005;209(2):165-167
PubMed   |  Link to Article
Kardaun SH, Sidoroff A, Valeyrie-Allanore L,  et al.  Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist?  Br J Dermatol. 2007;156(3):609-611
PubMed   |  Link to Article

Figures

Tables

Table Graphic Jump LocationTable. Clinical, Biologic, and Virologic Parameters at Baseline and After Treatment in the 6 Patients With DRESS Treated With IVIGs

References

Tohyama M, Hashimoto K, Yasukawa M,  et al.  Association of human herpesvirus 6 reactivation with the flaring and severity of drug-induced hypersensitivity syndrome.  Br J Dermatol. 2007;157(5):934-940
PubMed   |  Link to Article
Picard D, Janela B, Descamps V,  et al.  Drug reaction with eosinophilia and systemic symptoms (DRESS): a multiorgan antiviral T cell response.  Sci Transl Med. 2010;2(46):46ra62
PubMed   |  Link to Article
Fields KS, Petersen MJ, Chiao E, Tristani-Firouzi P. Case reports: treatment of nevirapine-associated dress syndrome with intravenous immune globulin (IVIG).  J Drugs Dermatol. 2005;4(4):510-513
PubMed
Kano Y, Inaoka M, Sakuma K, Shiohara T. Virus reactivation and intravenous immunoglobulin (IVIG) therapy of drug-induced hypersensitivity syndrome.  Toxicology. 2005;209(2):165-167
PubMed   |  Link to Article
Kardaun SH, Sidoroff A, Valeyrie-Allanore L,  et al.  Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist?  Br J Dermatol. 2007;156(3):609-611
PubMed   |  Link to Article

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics
PubMed Articles